MINI FUTURE SHORT - GILEAD SCIENCES | Delayed Deutsche Boerse AG 05:50:27 2024-07-05 EDT | ||
| 3.71 EUR | -0.27% |
|
| Current month | +4.20% | ||
| 1 month | -6.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 3.71 | -0.27% |
| 24-07-04 | 3.72 | +0.81% |
| 24-07-03 | 3.69 | +3.65% |
| 24-07-02 | 3.56 | +0.85% |
| 24-07-01 | 3.53 | -1.12% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 05:50 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE4RQN |
| ISIN | DE000PE4RQN1 |
| Date issued | 2022-11-02 |
| Strike | 106.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.16 € |
|---|---|
| Lowest since issue | 1.82 € |
| Spread | 0.03 € |
| Spread % | 0.80% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.59
USD
Average target price
82.97
USD
Spread / Average Target
+24.59%
- Stock Market
- Certificates
- Certificat
